Gadoversetamide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414599

CAS#: 131069-91-5

Description: Gadoversetamide is a nonionic, linear chelate used for magnetic resonance imaging of brain and spine.

Chemical Structure

img
Gadoversetamide
CAS# 131069-91-5
Instruction

Theoretical Analysis

MedKoo Cat#: 414599
Name: Gadoversetamide
CAS#: 131069-91-5
Chemical Formula: C20H37GdN5O10
Exact Mass: 665.18
Molecular Weight: 664.790
Elemental Analysis: C, 36.13; H, 5.61; Gd, 23.65; N, 10.53; O, 24.07

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Gadoversetamide; MP-1177; MP1177; MP 1177; HSDB7550; HSDB-7550; HSDB 7550

IUPAC/Chemical Name: (8,11-Bis(carboxymethyl)-14-(2-((2-methoxyethyl)amino)-2-oxoethyl)-6-oxo-2-oxa-5,8,11,14-tetraazahexadecan-16-oato(3-)), gadolinium

InChi Key: OKVNYJNFJCLPRF-UHFFFAOYSA-N

InChi Code: InChI=1S/C20H37N5O10.Gd/c1-34-9-3-21-16(26)11-24(14-19(30)31)7-5-23(13-18(28)29)6-8-25(15-20(32)33)12-17(27)22-4-10-35-2;/h3-15H2,1-2H3,(H,21,26)(H,22,27)(H,28,29)(H,30,31)(H,32,33);

SMILES Code: COCCNC1=O[Gd+3]234567N(CCN5(C1)CC([O-]6)=O)(CC([O-]7)=O)CCN2(CC(NCCOC)=O4)CC([O-]3)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 664.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Cheng KT. Gadoversetamide: Gd-DTPA-BMEA. 2007 Nov 7 [updated 2007 Dec 10]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641436.

2: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Gadoversetamide. 2019 Feb 28. PMID: 30000471.

3: Huber S, Muthupillai R, Cheong B, Wible JH Jr, Shah D, Woodard P, Grothues F, Mahrholdt H, Rochitte CE, Masoli O, Kim RJ, Schwaiger CM, Fuisz A, Kramer C, van Rossum AC, Biederman R, Lombardi M, Martin E, Kevorkian R, Flamm SD. Safety of gadoversetamide in patients with acute and chronic myocardial infarction. J Magn Reson Imaging. 2008 Dec;28(6):1368-78. doi: 10.1002/jmri.21502. PMID: 19025944.

4: Wible JH Jr, Tata PN, Napoli AM, Lowe LH, Kearns GL. Pharmacokinetics of gadoversetamide injection, a gadolinium-based contrast agent, in pediatric patients. Magn Reson Imaging. 2009 May;27(4):512-8. doi: 10.1016/j.mri.2008.08.002. Epub 2008 Sep 23. PMID: 18814985.

5: Lowe LH, Kearns GL, Wible JH Jr. The safety and efficacy of neuroimaging with gadoversetamide injection in pediatric patients. Curr Med Res Opin. 2006 Dec;22(12):2515-24. doi: 10.1185/030079906X159452. PMID: 17166334.

6: Wible JH Jr, Galen KP, Wojdyla JK. Cardiovascular effects caused by rapid administration of gadoversetamide injection in anesthetized dogs. Invest Radiol. 2001 May;36(5):292-8. doi: 10.1097/00004424-200105000-00007. PMID: 11394361.

7: Wible JH Jr, Troup CM, Hynes MR, Galen KP, MacDonald JR, Barco SJ, Wojdyla JK, Periasamy MP, Adams MD. Toxicological assessment of gadoversetamide injection (OptiMARK), a new contrast-enhancement agent for use in magnetic resonance imaging. Invest Radiol. 2001 Jul;36(7):401-12. doi: 10.1097/00004424-200107000-00006. PMID: 11496095.

8: Wible JH Jr, Hynes MR. Measurement of serum calcium concentration after administration of gadoversetamide in dogs. Radiology. 2004 Oct;233(1):158-64. doi: 10.1148/radiol.2331031689. PMID: 15454620.

9: Kim RJ, Albert TS, Wible JH, Elliott MD, Allen JC, Lee JC, Parker M, Napoli A, Judd RM; Gadoversetamide Myocardial Infarction Imaging Investigators. Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. Circulation. 2008 Feb 5;117(5):629-37. doi: 10.1161/CIRCULATIONAHA.107.723262. Epub 2008 Jan 22. PMID: 18212288.

10: Gandhi MJ, Narra VR, Brown JJ, Guo A, Grosu DS, Parvin CA, Scott MG. Clinical and economic impact of falsely decreased calcium values caused by gadoversetamide interference. AJR Am J Roentgenol. 2008 Mar;190(3):W213-7. doi: 10.2214/AJR.07.2923. PMID: 18287415.